Tango Therapeutics Expands ATM Offering to $400M

What Happened Tango Therapeutics, Inc. (TNGX) filed an 8-K on August 11, 2026 to disclose that it has terminated its prior $100 million at-the-market (ATM) prospectus supplement and filed a new prospectus supplement to increase the ATM program capacity to up to $400,000,000. The company originally entered the Sales Agreement with Leerink Partners LLC on November 21, 2025; as of the filing date Tango had sold about $64,389,566 of the prior $100,000,000 capacity and had $35,610,434 remaining, which is included in the new $400,000,000 offering.

Key Details

• Prior ATM capacity: $100,000,000 (entered Nov 21, 2025); approximately $64,389,566 sold.
• Unsold under prior supplement: ~$35,610,434, now folded into the new offering.
• New prospectus supplement filed: August 11, 2026 to offer up to $400,000,000 of common stock pursuant to the existing Sales Agreement with Leerink.
• Registration Statement (Form S-3ASR) is effective upon filing; Goodwin Procter LLP provided a legal opinion and consent related to the new supplement.

Why It Matters Expanding the ATM program gives Tango flexibility to raise capital by selling common stock into the market over time, which can fund operations, R&D, or other corporate needs without a single large equity offering. For investors, this means potential dilution if the company sells shares under the program; the timing and amount sold are at Tango’s discretion. The filing and effective registration indicate the company is prepared to access up to $400 million in equity capital as needed.